BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Ka:RAS Breaker Mechanism at the Fourth RAS Init...
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: GlobeNewswire
- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate BBO-8520, and its novel PI3Ka:RAS breaker mechanism which is in late lead optimization - KRASG12C GTP/GDP dual inhibitor BBO-8520 has shown significantly greater potency in KRAS models than first-generation KRAS G12C GDP-only inhibitors as measured by its ability to bind and covalently modify KRASG12C, block KRASG12C binding to effector proteins such as RAF, and inhibit downstream signaling - BBO-8520 was shown to retain potency in the context of receptor tyrosine kinase drive, which renders KRAS G12C GDP-only inhibitors inactive and is thought to be a major mechanism of non-response and resistance to these first-generation agents - BBO-8520 showed strong activity in KRASG12C in vivo models including deep regressions and differentiated efficacy compared to a first-generation KRAS
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewswire
- Noetik Appoints Dr. Shafique Virani as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 2/22/24 - Miss
BBIO
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- BBIO's page on the SEC website